KR100875335B1 - 신규 비스아미데이트 포스포네이트 프로드러그 - Google Patents

신규 비스아미데이트 포스포네이트 프로드러그 Download PDF

Info

Publication number
KR100875335B1
KR100875335B1 KR1020027008017A KR20027008017A KR100875335B1 KR 100875335 B1 KR100875335 B1 KR 100875335B1 KR 1020027008017 A KR1020027008017 A KR 1020027008017A KR 20027008017 A KR20027008017 A KR 20027008017A KR 100875335 B1 KR100875335 B1 KR 100875335B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
aryl
compound
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027008017A
Other languages
English (en)
Korean (ko)
Other versions
KR20020063248A (ko
Inventor
타오 자잉
스리니바스 라오 카시바틀라
라자 케이. 레디
Original Assignee
메타베이시스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타베이시스 테라퓨틱스, 인크. filed Critical 메타베이시스 테라퓨틱스, 인크.
Publication of KR20020063248A publication Critical patent/KR20020063248A/ko
Application granted granted Critical
Publication of KR100875335B1 publication Critical patent/KR100875335B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027008017A 1999-12-22 2000-12-22 신규 비스아미데이트 포스포네이트 프로드러그 Expired - Fee Related KR100875335B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17186299P 1999-12-22 1999-12-22
US60/171,862 1999-12-22
PCT/IB2000/002071 WO2001047935A2 (en) 1999-12-22 2000-12-22 Novel bisamidate phosphonate prodrugs

Publications (2)

Publication Number Publication Date
KR20020063248A KR20020063248A (ko) 2002-08-01
KR100875335B1 true KR100875335B1 (ko) 2008-12-22

Family

ID=22625436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027008017A Expired - Fee Related KR100875335B1 (ko) 1999-12-22 2000-12-22 신규 비스아미데이트 포스포네이트 프로드러그

Country Status (20)

Country Link
US (3) US6965033B2 (enExample)
EP (1) EP1240174A2 (enExample)
JP (1) JP2003519154A (enExample)
KR (1) KR100875335B1 (enExample)
CN (2) CN1740182A (enExample)
AU (1) AU784370B2 (enExample)
BR (1) BR0017048A (enExample)
CA (1) CA2396713A1 (enExample)
CZ (1) CZ301401B6 (enExample)
HK (1) HK1049841A1 (enExample)
HU (1) HUP0204092A3 (enExample)
IL (1) IL149887A0 (enExample)
MX (1) MXPA02006156A (enExample)
NO (1) NO20022932L (enExample)
NZ (1) NZ519219A (enExample)
PL (1) PL356525A1 (enExample)
RU (2) RU2273642C2 (enExample)
SK (1) SK8892002A3 (enExample)
WO (1) WO2001047935A2 (enExample)
ZA (1) ZA200204399B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
MXPA02008722A (es) 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
JP2004244409A (ja) * 2002-07-23 2004-09-02 Sankyo Co Ltd 糖尿病の発症予防薬
PT1576138T (pt) 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
BR0316868A (pt) * 2002-12-23 2005-10-25 Idenix Cayman Ltd Processo para a produção de pró-medicamentos de nucleosìdeo-3'
MXPA05008335A (es) * 2003-02-11 2006-05-04 Vernalis Cambridge Ltd Compuestos de isoxazol como inhibidores de las proteinas de choque por calor.
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
JPWO2005030236A1 (ja) * 2003-09-26 2006-12-07 株式会社スカイインターナショナル 肝臓内糖新生阻害作用を有する物質及びそれを含有する食品又は食品配合剤
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
WO2006002469A1 (en) 2004-07-02 2006-01-12 U.S. Filter Wastewater Group, Inc Gas transfer membrane
US8524794B2 (en) 2004-07-05 2013-09-03 Siemens Industry, Inc. Hydrophilic membranes
KR20070053764A (ko) * 2004-08-18 2007-05-25 메타베이시스 테라퓨틱스, 인크. 프럭토스 1,6-비스포스파타제의 신규한 티아졸 억제제들
EP1827664B1 (en) 2004-12-03 2011-06-08 Siemens Industry, Inc. Membrane post treatment
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200633702A (en) * 2004-12-15 2006-10-01 Sankyo Co Medicinal composition containing fbpase inhibitor
WO2006123765A1 (ja) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited フィルムコーティング製剤
EP1894930A4 (en) * 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
EP1901835B1 (en) 2005-07-14 2012-11-14 Siemens Industry, Inc. Monopersulfate treatment of membranes
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
MX2008015143A (es) 2006-06-01 2008-12-10 Hoffmann La Roche Derivados de tiazol.
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
EP2089017A2 (en) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
WO2008149346A2 (en) 2007-06-04 2008-12-11 Ben Gurion University Of The Negev Research And Development Authority Enhanced sensitivity polymerase chain reactions
EP2058308A1 (fr) 2007-11-12 2009-05-13 Merck Sante Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
WO2009073506A2 (en) * 2007-11-29 2009-06-11 Metabasis Therapeutics Inc. Nucleoside prodrugs and uses thereof
AU2008328956A1 (en) * 2007-11-30 2009-06-04 F. Hoffmann-La Roche Ag Pyridine compounds
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
RU2385870C1 (ru) * 2009-01-29 2010-04-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения n-замещенных (2-диалкоксифосфорил-4-циано)бутанамидинов
JP5690286B2 (ja) * 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
DK3366686T3 (da) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
KR102163611B1 (ko) * 2015-08-10 2020-10-08 머크 샤프 앤드 돔 코포레이션 항바이러스 베타-아미노산 에스테르 포스포디아미드 화합물
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
AU2017378893A1 (en) 2016-12-22 2019-05-16 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
EP3823629B1 (en) 2018-07-19 2024-12-25 Merck Sharp & Dohme LLC Phosphinic amide prodrugs of tenofovir
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3551422A (en) * 1968-03-27 1970-12-29 Stevens & Co Inc J P N-(oxymethyl) derivatives of phosphonopolyamino-s-triazines
US3822296A (en) * 1969-01-23 1974-07-02 Merck & Co Inc 1-trifluoromethyl-1,2-epoxyethyl-1-phosphonic acid and its salts
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
US4000305A (en) * 1972-09-27 1976-12-28 Imperial Chemical Industries Limited 15-, 16- AND 17-Indolyl or indolinyl nor prostanoic acid derivatives
GB1428137A (en) * 1972-09-27 1976-03-17 Ici Ltd Prostanoic acid derivatives
GB1516347A (en) * 1975-09-16 1978-07-05 Ici Ltd Process for the preparation of alkylphosphonate esters
US4092323A (en) * 1975-09-16 1978-05-30 Imperial Chemical Industries Limited Hydrazine derivatives of pyridyl-ketones
DE2855659A1 (de) * 1978-12-22 1980-07-03 Bayer Ag Benzimidazolyl-2-alkan-phosphonsaeuren
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DK277484A (da) * 1983-06-23 1984-12-24 Hoffmann La Roche Thiazolidinderivater
ATE72816T1 (de) * 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
US4728739A (en) * 1987-06-15 1988-03-01 American Home Products Corporation Hypoglycemic thiazolidinediones
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
DE59107135D1 (de) * 1990-01-18 1996-02-08 Ciba Geigy Ag Phoshponsäure- und Thionophosphonsäure-Derivate
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
US5116919A (en) * 1990-12-05 1992-05-26 E. I. Du Pont De Nemours And Company Process for increasing the relative viscosity of polyamides with reduced thermal degradation
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
US5142000A (en) * 1991-08-28 1992-08-25 E. I. Du Pont De Nemours And Company Process for increasing polyamide molecular weight with organophosphonic acid or ester catalysts in the presence of alumina-containing titanium dioxide
US5302586A (en) * 1991-12-19 1994-04-12 G. D. Searle & Co. Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5236941A (en) * 1992-06-30 1993-08-17 American Home Products Corporation 5-(2-hydroxy-1-arylethylidene)- and 5-(2-oxo-1-arylethylidene)-2,4-thiazolidinediones and derivatives thereof
JP2789134B2 (ja) * 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
DE4303648A1 (de) * 1993-02-09 1994-08-11 Basf Ag Verwendung von Aminovinylphosphonsäureestern als Lichtschutzmittel und Stabilisatoren für organisches Material
DE69426904T2 (de) * 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
CA2171743C (en) * 1993-09-17 2007-11-20 Norbert W. Bischofberger Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5728650A (en) * 1993-10-07 1998-03-17 Zeneca Limited Herbicidal aza bisphosphonic acids and compositions containing the same
US5468762A (en) * 1994-05-18 1995-11-21 American Home Products Corporation Azolidinediones as antihyperglycemic agents
US5532256A (en) * 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6147101A (en) * 1995-06-02 2000-11-14 Kyorin Pharmaceutical Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6001862A (en) * 1995-06-02 1999-12-14 Kyorin Pharameuticals Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same
EP0788353A1 (en) * 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
JP3500468B2 (ja) * 1995-12-27 2004-02-23 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
US6249316B1 (en) * 1996-08-23 2001-06-19 Flashpoint Technology, Inc. Method and system for creating a temporary group of images on a digital camera
US5861918A (en) * 1997-01-08 1999-01-19 Flashpoint Technology, Inc. Method and system for managing a removable memory in a digital camera
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
JP3610195B2 (ja) * 1997-07-04 2005-01-12 キヤノン株式会社 撮像装置
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO1999045016A2 (en) 1998-03-06 1999-09-10 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2289621A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
ATE300288T1 (de) * 1998-12-24 2005-08-15 Metabasis Therapeutics Inc Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
US6284672B1 (en) * 1999-03-02 2001-09-04 Advanced Micro Devices, Inc. Method of forming a super-shallow amorphous layer in silicon
JP2000278573A (ja) * 1999-03-23 2000-10-06 Minolta Co Ltd データ記憶媒体の駆動システム
JP4393652B2 (ja) * 1999-03-30 2010-01-06 株式会社リコー 撮像装置および文書撮影方法
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
MXPA02008722A (es) * 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
JP3914705B2 (ja) * 2000-11-29 2007-05-16 富士フイルム株式会社 ディジタル・カメラおよびその動作制御方法
KR100814426B1 (ko) * 2001-07-14 2008-03-18 삼성전자주식회사 다 채널 영상 중계 처리기 및 이를 적용한 다 채널 영상보안 시스템
US7015941B2 (en) * 2001-10-12 2006-03-21 Malloy Desormeaux Stephen G Hybrid cameras that download electronic images in selected geometric formats and methods
JP2003304482A (ja) * 2002-02-08 2003-10-24 Nikon Corp 電子カメラ
JP2004038515A (ja) * 2002-07-03 2004-02-05 Sanyo Electric Co Ltd データ記録装置
JP3781017B2 (ja) * 2002-07-22 2006-05-31 カシオ計算機株式会社 画像管理システム及び画像管理方法、デジタルカメラ
US20040156615A1 (en) * 2002-07-25 2004-08-12 Fuji Photo Film Co., Ltd Method and apparatus for image reproduction, method and apparatus for image recording, and programs therefor
US20050093998A1 (en) * 2003-11-03 2005-05-05 Haas William R. Digital camera with variable size delete buffer

Also Published As

Publication number Publication date
IL149887A0 (en) 2002-11-10
US6965033B2 (en) 2005-11-15
PL356525A1 (en) 2004-06-28
HUP0204092A2 (hu) 2003-03-28
US20090192121A1 (en) 2009-07-30
HK1049841A1 (zh) 2003-05-30
AU5244701A (en) 2001-07-09
JP2003519154A (ja) 2003-06-17
AU784370B2 (en) 2006-03-23
CN1434828A (zh) 2003-08-06
WO2001047935A2 (en) 2001-07-05
US20050004077A1 (en) 2005-01-06
NO20022932D0 (no) 2002-06-18
KR20020063248A (ko) 2002-08-01
EP1240174A2 (en) 2002-09-18
WO2001047935A3 (en) 2002-03-21
CN100595204C (zh) 2010-03-24
NO20022932L (no) 2002-08-22
US20020173490A1 (en) 2002-11-21
RU2002119708A (ru) 2004-03-20
CA2396713A1 (en) 2001-07-05
BR0017048A (pt) 2002-11-05
CZ20022172A3 (cs) 2003-01-15
RU2273642C2 (ru) 2006-04-10
ZA200204399B (en) 2003-11-26
HUP0204092A3 (en) 2005-02-28
RU2005138719A (ru) 2007-06-20
MXPA02006156A (es) 2003-09-22
SK8892002A3 (en) 2003-04-01
CN1740182A (zh) 2006-03-01
CZ301401B6 (cs) 2010-02-17
NZ519219A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
KR100875335B1 (ko) 신규 비스아미데이트 포스포네이트 프로드러그
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
KR100689943B1 (ko) 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
AU2006202624B2 (en) Novel bisamidate phosphonate prodrugs
AU2003242500B2 (en) Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
MXPA01002542A (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HK1075622A (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111216

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111216

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000